EPS for Concordia International Corp. (CXRX) Expected At $0.06; Tarena International Ads (TEDU) Sellers Increased By 50.3% Their Shorts

February 15, 2018 - By Michael Collier

Analysts expect Concordia International Corp. (NASDAQ:CXRX) to report $0.06 EPS on March, 21.They anticipate $0.00 EPS change or 0.00% from last quarter’s $0.06 EPS. CXRX’s profit would be $3.09 million giving it 2.87 P/E if the $0.06 EPS is correct. After having $0.06 EPS previously, Concordia International Corp.’s analysts see 0.00% EPS growth. The stock increased 2.23% or $0.015 during the last trading session, reaching $0.689. About 1 shares traded. Concordia International Corp. (NASDAQ:CXRX) has declined 95.85% since February 15, 2017 and is downtrending. It has underperformed by 112.55% the S&P500.

Tarena International Ads (NASDAQ:TEDU) had an increase of 50.3% in short interest. TEDU’s SI was 778,100 shares in February as released by FINRA. Its up 50.3% from 517,700 shares previously. With 466,800 avg volume, 2 days are for Tarena International Ads (NASDAQ:TEDU)’s short sellers to cover TEDU’s short positions. The SI to Tarena International Ads’s float is 2.09%. The stock increased 0.32% or $0.04 during the last trading session, reaching $12.37. About 44 shares traded. Tarena International, Inc. (NASDAQ:TEDU) has risen 81.27% since February 15, 2017 and is uptrending. It has outperformed by 64.57% the S&P500.




Concordia International Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company has market cap of $35.48 million. It operates through three divisions: Concordia International, Concordia North America, and Orphan Drugs. It currently has negative earnings. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies.

Among 9 analysts covering Concordia Healthcare Corp. (NASDAQ:CXRX), 4 have Buy rating, 2 Sell and 3 Hold. Therefore 44% are positive. Concordia Healthcare Corp. had 20 analyst reports since August 11, 2015 according to SRatingsIntel. The firm earned “Sector Outperform” rating on Tuesday, September 29 by Scotia Capital. The firm has “Outperform” rating given on Thursday, October 1 by RBC Capital Markets. The firm has “Speculative Buy” rating by Mackie given on Monday, October 19. The company was downgraded on Wednesday, February 8 by TD Securities. The stock of Concordia International Corp. (NASDAQ:CXRX) earned “Hold” rating by GMP Securities on Monday, August 15. On Monday, August 15 the stock rating was maintained by Goldman Sachs with “Neutral”. The firm earned “Sector Outperform” rating on Friday, October 16 by Scotia Capital. The stock has “Sector Perform” rating by IBC on Monday, November 30. The firm has “Hold” rating given on Thursday, August 4 by TD Securities. The stock has “Sector Perform” rating by Scotia Capital on Monday, September 19.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.